Everolimus-Associated Thrombotic Microangiopathy and Acute Kidney Injury in a Patient with Breast Cancer

Ersan S., Peker A., GÜLLE S., Yilmaz Avcioglu B.

TURKISH NEPHROLOGY DIALYSIS AND TRANSPLANTATION JOURNAL, cilt.25, ss.86-88, 2016 (ESCI) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 25
  • Basım Tarihi: 2016
  • Doi Numarası: 10.5262/tndt.2016.17
  • Dergi Adı: TURKISH NEPHROLOGY DIALYSIS AND TRANSPLANTATION JOURNAL
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.86-88
  • Anahtar Kelimeler: Everolimus, Thrombotic microangiopathy, Breast cancer, HEMOLYTIC-UREMIC SYNDROME, COMBINATION
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Thrombotic microangiopathy is a pathological condition caused by several factors including drugs, and characterized by endothelial injury and small vessel occlusion. It may cause severe acute kidney injury. Everolimus, a mammalian target of Rapamycin inhibitor, is a macrolide antibiotic widely used in clinical conditions because of its anticancer and immunosuppressive effects. Recently it has been approved for use in breast cancer at a dose of 10 mg/day in combination with exemestane, an aromatase inhibitor. In the literature a few cases of everolimus-induced thrombotic microangiopathy and acute kidney injury in breast cancer patients have been reported. Here we reported the management of a breast cancer patient with everolimus-induced thrombotic microangiopathy and severe acute kidney injury with emphasis on close monitoring of kidney functions.